Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents.
We compared rates of recurrent Clostridium difficile infection in patients receiving or not receiving oral vancomycin prophylaxis with systemic antimicrobial therapy. The incidence of C. difficile infection was significantly lower in patients receiving prophylaxis (4.2% vs 26.6% in those without prophylaxis; odds ratio, 0.12; 95% confidence interval, .04-.4; P < .001).
Department of Pharmacy, Edward-Elmhurst Hospitals, Naperville, Illinois.
Nicholas W
NW
Van Hise
Department of Pharmacy.
Alex M
AM
Bryant
Department of Pharmacy Department of St Louis College of Pharmacy, Missouri.
Erin K
EK
Hennessey
Department of Pharmacy Department of St Louis College of Pharmacy, Missouri.
Andrew J
AJ
Crannage
Department of Medicine, Mercy Hospital St Louis.
Jad A
JA
Khoury
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Farrin A
FA
Manian
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D016360:Clostridioides difficile; D003015:Clostridium Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D012189:Retrospective Studies; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014640:Vancomycin
Clostridium difficile; antimicrobial agents; prophylaxis; vancomycin